ArticleUltrasound international open2026
Contrast-enhanced Perfusion Measurements in Patients with Active Crohn's Disease Using Sonazoid.
Article in Ultrasound international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess the feasibility of dynamic contrast-enhanced ultrasound with Sonazoid, its correlation with disease activity, its ability to differentiate between remission/mild activity and moderate/severe activity, and if a region of interest including the mucosa and submucosa was different compared to one encompassing the entire wall. Materials and methods: We prospectively studied 48 patients with Crohn's disease who underwent colonoscopy and dynamic contrast-enhanced ultrasound with Sonazoid from 2015 to 2019. We compared the local simple endoscopic score for Crohn's disease in the most affected area with parameters from Vuebox, including peak enhancement, wash-in and wash-out area under the curves, wash-in and wash-out rates, and wash-in perfusion index. Region of interest-1 (ROI-1) included all wall layers, and region of interest-2 (ROI-2) included the mucosa and submucosa. Linear data and normalised data were used. Technical failure or a quality of fit value of<80% was considered a failed examination. Results: The feasibility of the dynamic contrast-enhanced ultrasound examination was 73%. No significant findings were noted in the linear data ( Conclusions: Dynamic contrast-enhanced ultrasound parameters can differentiate between remission/mild and moderate/severe activity in Crohn's disease, but the method has relatively low feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.